Navigation Links
Ranbaxy Launches Authorized Generic Of Pioglitazone In The U.S.
Date:8/17/2012

PRINCETON, N.J., Aug. 17, 2012 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL), has launched authorized generic pioglitazone hydrochloride tablets in the U.S. market, under an agreement with Takeda Pharmaceuticals U.S.A., Inc.Pioglitazone hydrochloride tablets is an oral antidiabetic agent that acts primarily by decreasing insulin resistance, presently distributed by Takeda Pharmaceuticals America, Inc. under the brand name Actos. The product is indicated for patients as an adjunct to diet and exercise to improve glycemic controls in adults with type 2 diabetes mellitus.  Actos® generated total annualized sales of $2.7 billion in the U.S. (IMS – MAT June 2012).

Bill Winter, Vice President, Trade Sales and Distribution, North America, said, "Ranbaxy is making available the full range of generic pioglitazone in 15 mg, 30 mg, and 45 mg tablets.  The introduction of generic pioglitazone hydrochloride tablets is a significant and important addition to our portfolio of antidiabetic products in the U.S.  The launch further complements our resolve to bring high quality, affordable generic medicines as early as possible to the U.S. healthcare system."

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals, in developed and emerging markets many of which incorporate proprietary Novel Drug Delivery Systems (NDDS) and technologies, developed at its own labs. The company has further strengthened its focus on generics research and is increasingly working on more complex and specialty areas. Ranbaxy serves its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Through strategic in-licensing opportunities and its hybrid business model with Daiichi Sankyo, a leading global pharma innovator headquartered in Tokyo, Japan, Ranbaxy is introducing many innovator products in markets around the world, where it has a strong presence. This is in line with the company's commitment to increase penetration and improve access to medicines, across the globe. For more information, please visit www.ranbaxy.com.

Actos is a trademark of Takeda Pharmaceutical Company Limited registered in the U.S. Patent and Trademark Office.CONTACTS:

Charles M. Caprariello

Robert FerrisVice President, Corporate Communications

RF Binder Partners Inc.Ranbaxy Inc.

(212) 994-7505(609) 720-5615
'/>"/>

SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ranbaxy Announces U.S. FDA Approval of CIP-Isotretinoin NDA
2. Ranbaxy Commends New IMS Study Which Credits Generic Prescription Drugs With $1 Trillion Savings In U.S. Health Care Costs Over Past 10 Years
3. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
4. SurgLine International, Inc. Launches A Wholly Owned Operating Subsidiary To Pursue Cost Containment Strategies
5. Mylan Launches Generic Version of Zyprexa® Tablets
6. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
7. American Academy of Family Physicians Foundation Launches Cities for Life
8. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
9. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
10. Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com
11. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... 2017  May is Stroke Awareness Month and Omron ... important methods to prevent a stroke: monitor and manage ... Control and Prevention, undetected and uncontrolled hypertension is a ... global leader in personal heart health technology, recently evolved ... attack and stroke and is advancing a national public ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)... 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... data solutions, today announced that it is teaming up ... Technologies Limited to lower diabetes healthcare costs in ... card, which is available throughout all provinces and territories ... be eligible for additional savings when shopping for Dario ...
Breaking Medicine Technology:
(Date:5/19/2017)... (PRWEB) , ... May 19, 2017 , ... ... RawTrition’s BioEnergy in an upcoming episode of Innovations with Ed Begley, Jr., airing ... RawTrition is the distributor of a clean, organic dietary supplement made from naturally ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Hill Agencies, a family ... entrepreneurs throughout the California Central Valley, is announcing a joint charity initiative with the ... for a local kid’s camp event. , The Boys and Girls Club of Kern ...
(Date:5/19/2017)... ... 2017 , ... SyncDog, Inc. , the leading ISV ... 7th Annual ET6 Exchange (formerly M6 xChange), the Enterprise Transformation Conference. ... expressed purpose is to connect mobile technology end users with industry experts and ...
(Date:5/19/2017)... AZ (PRWEB) , ... May 18, 2017 , ... CloSYS ... known for being non-irritating while extremely helpful for mouth and gum health, which is ... introduced their professionals and customers learned quickly of the powerful ways in which CloSYS ...
(Date:5/18/2017)... , ... May 18, 2017 , ... Dr. Kim Ross ... and educating her community on the link between this condition and serious systemic health ... to severe periodontal disease in Annapolis, MD, and seeking treatment with Dr. ...
Breaking Medicine News(10 mins):